Acta Veterinaria et Zootechnica Sinica ›› 2025, Vol. 56 ›› Issue (6): 3027-3031.doi: 10.11843/j.issn.0366-6964.2025.06.044

• Research Notes • Previous Articles     Next Articles

Immunogenicity Analysis of Recombinant Adenovirus Expressing African Swine Fever Virus (ASFV) pp62 and Hsp70 Proteins in Mice

CHEN Changchun(), WU Zhi, REN Guanyu, CHEN Wenyu, CAO Shinuo, ZHU Rui, ZHANG Li, CHENG Yuting, ZHU Shanyuan, LU Huipeng*()   

  1. Jiangsu Agri-animal Husbandry Vocational College, Taizhou 225300, China
  • Received:2024-07-26 Online:2025-06-23 Published:2025-06-25
  • Contact: LU Huipeng E-mail:chenchangchun66@126.com;luhuipeng@jsahvc.edu.cn

Abstract:

The aim of this study was to develop a recombinant adenovirus vaccine against African swine fever virus (ASFV) to provide a scientific basis for the clinical application and development of ASFV vaccines. We constructed a recombinant adenovirus (rAd-CP530R-Hsp70) expressing the fusion of ASFV CP530R gene and Mycobacterium tuberculosis heat shock protein 70 (Hsp70) using the pAdEasy-1 system. The expression of the target protein was verified by indirect immunofluorescence and Western blot. Mice were immunized with the rAd-CP530R-Hsp70 recombinant adenovirus, and the levels of antibodies and cytokines produced in the mice were detected. Results were as follows: The recombinant adenovirus successfully induced mice to produce specific antibodies against pp62, with antibody titers reaching 1.33 at 35 days post-immunization. The levels of IL-2, IL-4, and IFN-γ in the supernatant of mouse splenocyte cultures were significantly increased after immunization, indicating that the vaccine could effectively activate both humoral and cellular immune responses. The constructed recombinant adenovirus vaccine can effectively induce an immune response in mice, providing data support for the development of African swine fever vaccines.

Key words: African swine fever virus, CP530R, recombinant adenovirus, Hsp70

CLC Number: